Compare Danaher Corporation (DHR) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares MSCI Germany (DAX) — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while iShares MSCI Germany (DAX) trades at $40.96 (market cap $1.42B). The key difference: Danaher Corporation is far larger — about 107.7× iShares MSCI Germany (DAX)'s market cap, and Danaher Corporation pays a 0.74% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares MSCI Germany (DAX) for 54 Days on average.
| DHR | EWG | |
|---|---|---|
Market Cap | $152.87B | $1.42B |
Volume | 5,228,698 | 1,110,573 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $44.59 |
52-Week Low | $161.91 | $38.08 |
Typical Hold Time | 69 Days | 54 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
EWG is trading at $40.67, down 0.59% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $41 with support at $40. Recent European market news highlights ECB rate hikes and energy price concerns affecting regional equities, though some analysts note resilience in European stocks despite macroeconomic pressures.
The bearish technical indicators and European economic uncertainty create near-term headwinds. Investment opportunity exists if the stock holds above $40 support, but risks include further ECB tightening and energy-driven inflation. Upside potential requires breaking above $41 resistance with improved market sentiment toward European equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
